Megestrol
Sponsors
Merck Sharp & Dohme LLC, National Center for Research Resources (NCRR), Centre Oscar Lambret, Ann Davis, PhD, MPH, ABPP, University of Sao Paulo
Conditions
Acquired Immunodeficiency SyndromeAnorexiaBreast cancerCachexia; CancerCancerChemotherapy-induced Nausea and VomitingChronic Oral Food RefusalEndometrial cancer
Phase 2
Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
CompletedNCT00420563
Start: 2009-09-25End: 2011-01-19Updated: 2026-03-16
Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age
CompletedNCT01206478
Start: 2010-08-31End: 2014-12-31Updated: 2016-08-15
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
CompletedNCT03283488
Start: 2019-03-26End: 2022-02-02Updated: 2023-07-07
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
NCT04430361
Start: 2018-09-07End: 2021-05-30Target: 120Updated: 2020-06-12
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
RecruitingCTIS2024-519563-18-00
Start: 2025-09-02Target: 22Updated: 2025-10-14